Pharmaceuticals Ltd has announced having entered into
an agreement with one of China''s largest pharma companies
to exclusively market its blockbuster drug, Cardio-tonic
pill, in India.
Chinese company, Tasly, sells Cardiotonic in 13 countries,
including the US, where the drug, approved by the US FDA,
has sales of $30 milli9on out of its global sales of $360
million. Torrent says the drug is the highest-selling
single medicine in China, with sales of over $160 million.
Torrent believes it has a potential blockbuster in its
hands and expects to prop its topline with sales of around
Rs20 crore within two years of its launch.
is a novel oral droplet formulation based on the theory
of traditional Chinese medicine used for the treatment
and prevention of cardiovascular diseases like coronary
artery disease (CAD), diabetes and hypertension.
is made from a unique combination of pure extracts of
three Chinese medicinal herbs radix salviae miltiorrhizae,
radix notoginseng and bormel cardiotonic is manufactured
with modern pharmaceutical technology and strict quality
innovative droplet pill formulation offers many clinical
advantages such as low dosage, rapid and complete absorption,
fast onset of action, high potency with few side effects,
to Ruchir Modi, head, strategic marketing, Torrent Pharmaceuticals,
"All current C&D (cardio-diabeta) therapies prescribe
a wide array of add-ons like vitamin E, folic acid and
neurogenic supplements. Cardiotonic will be positioned
as a single add-on solution in cardiovascular disorders
for all cardiologists, diabetologists and consultant physicians
and will do away with the need for multiple add-ons. It
will be the most preferred "add on" therapy
in CV disorders."
also says that this in-licensing deal is first of its
kind in India in the traditional medicine segment. Torrent
Pharmaceuticals will be exploring more such exclusive
avenues in the medium to long term to get sole licenses
to market such products.
pill finds perfect synergy with the Torrents dominant
position in the Indian cardio-diabeta (C&D) market.
The company is ranked second in the cardiology market
with a growth rate of around 15 per cent and is one of
the fastest growing in the oral anti-diabetic therapy
segment in India.
says that it was the first to launch global blockbusters
like atenolol, rosiglitazone and repaglinide in India
and enjoys market leadership in many brands in the cardiology
Pill is just one of the many potentially blockbuster products
in the portfolio of OMEGA, the Company''s new specialty
division that focuses on the Cardio metabolic diseases,
with exclusive focus on cardiology, diabetes and nephrology.
deal comes at a time when India is poised to become the
country with the largest number of patients suffering
from cardio-vascular diseases. According to WHO, India
will have 57 million diabetics
by 2025 and the prevalence of other associated diseases
is going to increase in similar fashion. Currently, 7%
of Indians suffer from various cardio-vascular diseases,
4% are diabetics and 7% are hypertensives.